13-May-2015 teleSUR On Monday, a coalition of Peruvian civil society organizations issued a strong warning as negotiations for the Trans Pacific Partnership treaty (TPP) come to an end.
Statement of May 2011 against the increasingly rapid spread of Free Trade Agreements that put the profits of multinational pharmaceutical companies ahead of people’s right to health around the world.
India formally announced at the UN High Level Meeting on HIV and AIDS that it will not accept data exclusivity, a provision harmful to access to affordable medicines, as part of a free trade agreement currently being negotiated with the European Union.
The TPP chapter may be best seen as a significant step toward the pharmaceutical industry’s ultimate goal, which is a binding international agreement on drug pricing that would restrain the ability of governments to use collective purchasing power to demand prices below “market” levels.
Pharmac is being targeted by US drug companies as trade negotiations continue with the United States.
As the global community meets in New York for the United Nations General Assembly High Level Meeting on HIV and AIDS from 8 to 10 June 2011, networks of People living with HIV, health groups and treatment activists from around the world are calling for an immediate moratorium on all Free Trade Agreements (FTAs) and TRIPS-plus measures.
Canadians spend a lot of money (public and private) on health care and much of that is spent on drugs — some $23.4 billion in 2008. Provincial insurance plans are desperately trying to cope, looking to initiatives like the recently passed Ontario law that caps prices of generic drugs at 25 per cent of the brand name equivalent.
Labour leader Phil Goff says his party would not put government drug buying agency Pharmac on the block to gain a free trade deal with the United States.
Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other developing countries
KEI has received a copy of a May 16, 2011 letter from Karl De Gucht to Andris Piebalgs, which discusses (1) the EU-India FTA, and (2) Relations between IPR and development policies.
The Green Party is calling on the Government to take Pharmac off the table in Trans Tasman Partnership (TTP) negotiations.
Some of New Zealand’s most prominent businesspeople are rallying to the support of drug buying body Pharmac as lobbying firm Saunders Unsworth mounts a campaign against the agency ahead of free trade negotiations with the US.
12-May-2011 FDA News
US pharmaceutical industry association the Pharmaceutical Research and Manufacturers of America is calling on the US Trade Representative to include strong intellectual property provisions, such as 12-year data protection for follow-on biologics, in the Trans-Pacific Partnership agreement.
Nations currently negotiating trade deals with the European Union (EU) have been warned that they must resist European demands which could threaten access to medicines in emerging and developing countries.
India will not compromise its stand or take a position on intellectual property rights (IPR), especially on pharmaceuticals, beyond its domestic law and agreements as mandated under the aegis of the global trade body—World Trade Organization (WTO).
1-May-2011 ANSA Latina
BUENOS AIRES, 1 (ANSA) - Los laboratorios de capital nacional de América Latina debatirán a partir de mañana en El Salvador sobre las consecuencias de los tratados de libre comercio en la región y sobre la imposición de trabas aduaneras, que alientan la concentración monopólica de los mercados farmacéuticos.
13-Apr-2011 ActUp Paris
Par le passé, les États-Unis ont signé avec des pays en développement des accords de libre-échange (ALE), aux effets désastreux sur les coûts des médicaments. Depuis quelques années, c’est au tour de l’Europe, sous l’impulsion de la France, du Royaume-Uni et de l’Allemagne, de prendre le relais de cette politique bilatérale, lourde de conséquences pour les malades.
After four years of talks, India and the European Union are narrowing down their differences on a bilateral Free Trade Agreement that critics in India and elsewhere say could have a devastating impact on public health by hampering access to life-saving drugs for millions of people.
As free trade agreement talks between Europe and India resume in Brussels today, the international medical humanitarian organisation Médecins Sans Frontières (MSF) is deeply concerned about new measures Europe is pushing to restrict the production of affordable generic medicines that MSF and others rely on to treat patients across the developing world.
India today ruled out sharing test data of drugs, or data exclusivity, of Indian pharma firms with developed countries and multi-national companies, and stressed that the provision will not form part of any free trade agreements pursued by the country.
L’accord, en négociation depuis trois ans, pourrait mettre un coup d’arrêt à la production de médicaments génériques en Inde.
Eleven public interest advocacy groups and three law professors have submitted a petition to Anand Grover, the Special Rapporteur for the United Nations on the right to health, to intervene in a new regional trade agreement that will shrink the market for legal generic medecines.